Applied Therapeutics Drug Is Denied FDA Approval in Rare Inherited Metabolic Disease

The FDA cited deficiencies in its govorestat’s application in galactosemia, a rare metabolic disease, Applied Therapeutics said. The biotech is still on track to submit a separate application for the drug in sorbitol dehydrogenase (SORD) deficiency, another rare disease that has no FDA-approved therapies.

The post Applied Therapeutics Drug Is Denied FDA Approval in Rare Inherited Metabolic Disease appeared first on MedCity News.

Leave a Reply

Your email address will not be published. Required fields are marked *